Shots:
- Lineage to receive an upfront payment in cash and, if the option is exercised, Lineage will be eligible for additional payments, including event-specific payments, royalties on net sales and sublicense fees and royalties
- Amasa gets an exclusive option to royalty-bearing license to use Lineage’s HyStem technology to develop and commercialize therapies for solid tumors under pre-negotiated terms
- Amasa will buy some amounts of Lineage’s existing supply of clinical-grade HyStem biomaterial and has the right to buy additional quantities in up to 12-mos. option to acquire the exclusive license
Click here to read full press release/ article | Ref: Business Wire | Image: Lineage Cell
The post Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem first appeared on PharmaShots.
